Home / Peptide legality / By country / Italy
Are peptides legal in Italy?
Peptides are legal in Italy only as prescription medicines: approved peptide drugs like semaglutide (GLP-1) and somatropin (HGH) require a doctor's prescription, while unapproved 'research' peptides such as BPC-157 and TB-500 are not authorized for human use and cannot be lawfully sold or supplied for human consumption in Italy.
Legal status overview
Peptides in Italy are restricted: they are lawful only through the regulated medicines system, meaning approved peptide-based drugs are prescription-only and unapproved research peptides have no legal channel for human use. The Agenzia Italiana del Farmaco (AIFA), together with the Ministry of Health and the EU-level European Medicines Agency (EMA), controls which peptide medicines are authorized and how they are prescribed and reimbursed. GLP-1 peptides such as semaglutide require a prescription and are reimbursed only for type 2 diabetes under AIFA Note 100, while peptides like BPC-157 that no regulator has approved are treated as unapproved substances.
Key points
- In Italy, GLP-1 peptide medicines (semaglutide, dulaglutide, liraglutide, exenatide and the GIP/GLP-1 agonist tirzepatide) all require a medical prescription, according to AIFA. [1]
- AIFA is Italy's national medicines regulator (its equivalent of the U.S. FDA), and all major GLP-1 peptide products reach the Italian market only after EMA/AIFA authorization and are dispensed in pharmacies with a valid Italian prescription. [7]
- AIFA has formally warned that using Ozempic® (semaglutide) for weight management is off-label, stating the drug is indicated exclusively for type 2 diabetes and that other uses jeopardize supply for diabetic patients (notice published 6 March 2023). [2]
- In Italy, semaglutide is reimbursed by the National Health Service only for type 2 diabetes under AIFA Note 100, while the weight-loss formulation (Wegovy®) is sold at the patient's full cost in non-reimbursed Band C. [3]
- AIFA authorized Wegovy®, the semaglutide medicine specifically indicated for weight loss, for the Italian market in 2024, placing it in Band C of non-reimbursed medicines available in pharmacies. [4]
- BPC-157 is not approved by any drug regulatory agency for human use, and the European Medicines Agency has not authorized it for any medical indication, so in Italy it exists only as an unapproved substance rather than a lawful medicine. [5]
- No Italy-specific statute setting out personal-import allowances (such as a permitted days'-supply) for peptides was located in this research; bringing prescription peptide medicines into Italy generally follows the EU/Italian rule that they must correspond to a legitimate personal medical prescription, and this point reflects general medicines-law inference rather than a directly cited Italian import rule. (no source found)
Compound-by-compound status
| BPC-157 | BPC-157 is an unapproved substance in Italy, as neither the EMA nor any drug regulatory agency has authorized it for human use, meaning it is available only as an unregulated 'research chemical' and cannot be lawfully marketed for human consumption. [6] |
|---|---|
| Semaglutide (GLP-1, e.g. Ozempic®/Wegovy®/Rybelsus®) | Semaglutide is a legal, prescription-only medicine in Italy, reimbursed by the National Health Service only for type 2 diabetes under AIFA Note 100, while its weight-loss brand Wegovy® is patient-paid in non-reimbursed Band C. [3] |
| Tirzepatide (Mounjaro®, GIP/GLP-1) | Tirzepatide is a legal, prescription-only medicine in Italy, reimbursed for type 2 diabetes under AIFA Note 100 alongside the GLP-1 analogues. [1] |
| TB-500 (thymosin beta-4) | TB-500 appears to have no marketing authorization as a medicine in Italy and would fall into the same unapproved-substance category as other research peptides, but no source directly addressing TB-500's status in Italy was found in this research, so this classification is inference rather than a cited fact. (no source found) |
| Human growth hormone (HGH / somatropin) | HGH/somatropin is a prescription-only medicine in Italy dispensed through the regulated pharmacy system, but no Italy-specific source confirming its scheduling was retrieved in this research, so this reflects general knowledge of its EU medicine status rather than a directly cited Italian source. (no source found) |
Frequently asked questions
Can I buy peptides in Italy without a prescription?
No, in Italy, authorized peptide medicines such as semaglutide and other GLP-1 drugs are prescription-only and dispensed by pharmacies, and unapproved peptides like BPC-157 have no legal retail channel for human use at all. [1]
Is BPC-157 legal in Italy?
BPC-157 is not an approved medicine in Italy; because the EMA has not approved it for any indication and no regulator authorizes it for human use, it circulates only as an unapproved 'research chemical' and cannot be lawfully sold for human consumption. [6]
Can I get semaglutide (Ozempic®/Wegovy®) for weight loss in Italy?
Yes, but only with a prescription and usually at your own cost: in Italy semaglutide is reimbursed by the National Health Service only for type 2 diabetes under AIFA Note 100, while the weight-loss brand Wegovy® is a patient-paid, non-reimbursed (Band C) pharmacy medicine. [3]
Is it legal to use Ozempic® for weight loss in Italy?
Using Ozempic® for weight loss in Italy is considered off-label by AIFA, which has stated the drug is indicated exclusively for type 2 diabetes and warned that other uses put supply for diabetic patients at risk; a prescriber remains legally responsible for any off-label decision. [2]
Can I bring peptides into Italy for personal use when travelling?
You should generally carry only authorized prescription peptide medicines accompanied by a legitimate personal prescription; no Italy-specific personal-import quantity rule for peptides was found in this research, so travellers should verify current requirements with the Italian Ministry of Health or customs before travelling. (no source found)
Sources
- AIFA, New medicines for type 2 diabetes and obesity: AIFA guide to responsible use (retrieved 2026-09-22)
- AIFA, Direct communication with healthcare professionals on Ozempic® (semaglutide) (retrieved 2026-09-22)
- SISMED, Semaglutide and tirzepatide in Italy: costs, reimbursement, and who prescribes (retrieved 2026-09-22)
- AIFA, 2024 OsMed Report press communication (Comunicato AIFA 24-2024) (retrieved 2026-09-22)
- Wikipedia, BPC-157 (retrieved 2026-09-22)
- 50 Best Peptides, Is BPC-157 Legal? A Country-by-Country Guide (retrieved 2026-09-22)
- Regimen, GLP-1 in Italy 2026: Ozempic®, Mounjaro® Pricing & SSN Access (retrieved 2026-09-22)
- USADA, BPC-157: Experimental Peptide Creates Risk for Athletes (retrieved 2026-09-22)
Last researched: 2026-09-22.